Join to View Full Profile
40 Duke Medicine CirDurham, NC 27710
Phone+1 919-684-8111
Dr. Harrison is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 2007 - 2009
Tulane UniversityResidency, Internal Medicine, 2004 - 2007- Tulane University School of MedicineClass of 2004
Certifications & Licensure
NC State Medical License 2011 - 2026
WI State Medical License 2007 - 2011
LA State Medical License 2005 - 2007
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
- RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017) Start of enrollment: 2014 Mar 01
- Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis Start of enrollment: 2015 Jul 01
Publications & Presentations
PubMed
- A Breakthrough From China in a Rare Form of Kidney Cancer.Daniel J George, Michael R Harrison
JAMA Oncology. 2025-08-14 - Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.Ryan E Fecteau, Bridget F Koontz, Karen E Hoffman, Susan Halabi, Lauren E Howard
Prostate Cancer and Prostatic Diseases. 2025-06-01 - 1 citationsIntensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The...Tian Zhang, Lauren Howard, Bridget F Koontz, Scott T Tagawa, Himanshu Nagar
European Urology Oncology. 2025-04-01
Press Mentions
Drug Combo Shows Benefits in Rare, Aggressive Kidney CancerAugust 15th, 2025
Immunotherapy Agents Improve Outlook for Advanced Bladder CancerAugust 13th, 2019
Cabozantinib RCC Benefit Highlighted as Frontline Approval ApproachesNovember 15th, 2017- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
